Chief Financial Officer of Inovio in 2002 - Assignment Example

Before becoming the Chief Financial Officer of Inovio in 2002, Peter acquired a wide experience in the strategic and functional management of high technology and biotechnology companies. His experience includes corporate growth, which includes from IPO to profitability. Mr. Peter holds a BSc. Degree in Business Administration from USIU (United States International University, San Diego.

Scientific Advisory Board
David B. Weiner, Ph.D.
David is a widely known leader in gene therapy, vaccines, and immunology. He has over 300 peer-reviewed journals as a leading forerunner in the DNA vaccines field. Before becoming chairman of the Inovio Board of Directors, Weiner was an editor with several scientific published works like DNA Vaccine Meeting 2010, Biological active peptides, and Design, Synthesis, and Utilization. Dr. Weiner has a Bachelor of Science in Biology from SUNY at Stony Brook and an M.S. in Biology from the University of Cincinnati.

Philip D. Greenberg, MD

Dr. Philip is the Head of the Program of immunology at Inovio Pharmaceuticals. He is also a professor of Medicine and immunology at the University of Washington. Dr. Philip holds a degree in biology from Washington University. He worked at Fred Hutchinson Cancer Research Center. In 1971, he received his M.D. from the State University of New York.
Question 2
VGX-3100 is an experimental therapy that is designed to remove precancerous cervical lacerations. It also clears HPV infection with robust T-cell responses. The therapy is administered depending on the age and severity of HPV.

Question 3
The mechanism of action of VGX-3100 is that of inducing regression of precancerous cervical lesions. VGX-3100 is an immunotherapy that has two DNA plasmids that target the E6 and E7 oncogenes of HPV categories 16 and 18. The oncogenes are responsible for the transformation of cells that are infected with HPV into precancerous cells.
Question 4
Study locations include the States of Florida, Boynton Beac,h and Lakewood, Colorado in the United States.

Question 5
Inovio Pharmaceuticals has the quest of revolutionizing vaccines, therefore combing two distinct technologies. First, the company uses synthetic vaccines that are not only designed for prevention but also to treat diseases. Second, the company’s electroporation vaccine delivery technology plays a crucial role in enabling fast body immune responses from synthetic vaccines. Read More